news

Organ-on-a-Chip and 3D-Printing in the Life Sciences Conference, Boston, July 8-9, 2015 features international roster of speakers.

Posted: 8 June 2015 | Select Biosciences

Select Biosciences is delighted to announce that its Organ-on-a-Chip and 3D-Printing in the Life Sciences Conference, Boston, July 8-9, 2015 features all the international key opinion leaders in the organ-on-a-chip/body-on-a-chip field as well as 3D-bioprinting fields…

Select Biosciences Second Annual Organ-on-a-Chip World Congress and 3D-Culture, July 7-8, 2016, Boston, USA.

Select Biosciences is delighted to announce that its Organ-on-a-Chip and 3D-Printing in the Life Sciences Conference, Boston, July 8-9, 2015 features all the international key opinion leaders in the organ-on-a-chip/body-on-a-chip field as well as 3D-bioprinting fields.

The 3D-printing field is expanding exponentially and it is starting to impact the life sciences arena.  The current interest in this space is the use of various bioinks to “print” parts of tissues in the goal and hope to bioprint organs as well as body parts in the future for regenerative medicine and other medical applications.  This conference explores 3D-printing in the life sciences via presentations from academic researchers as well as industry participants.  Several companies involved in bioprinting and bioinks will be exhibiting at this conference.

The companion conference track explores Organ-on-a-Chip/Body-on-a-chip which employs the use of microfluidics and lab-on-a-chip (LOAC) technologies to build “cell clusters in 3D-format” in functionally-relevant patterns.  These patterns enable cellular function to be recapitulated ex vivo and has wide-ranging potential for drug discovery and development applications in the pharmaceutical and biotechnology industries.

 

Access your FREE copy

 


Biomarkers aren’t just supporting drug discovery – they’re driving it

FREE market report

From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.

What you’ll unlock:

  • How biomarkers are guiding dose selection and early efficacy decisions in complex trials
  • Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
  • What makes lab data regulatory-ready and why alignment matters from day one

Explore how biomarkers are shaping early drug development

Access the full report – it’s free!

 

The conference website for this 2-track event is: http://goo.gl/tcbz9f

For More Information about this Conference, please contact Jeff Fan, Events Manager, Select Biosciences, Inc.  Telephone: +1-510-857-4865.  E-mail: [email protected]